Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Antidepressant-like activity of a brain penetrant HCN channel inhibitor in mice

Open access

Abstract

Changes in Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) channel function have been linked to depressive-like traits, making them potential drug targets. However, there is currently no peer-reviewed data supporting the use of a small molecule modulator of HCN channels in depression treatment. Org 34167, a benzisoxazole derivative, has been patented for the treatment of depression and progressed to Phase I trials. In the current study, we analysed the biophysical effects of Org 34167 on HCN channels in stably transfected human embryonic kidney 293 (HEK293) cells and mouse layer V neurons using patch-clamp electrophysiology, and we utilised three high-throughput screens for depressive-like behaviour to assess the activity of Org 34167 in mice. The impact of Org 34167 on locomotion and coordination were measured by performing rotarod and ledged beam tests. Org 34167 is a broad-spectrum inhibitor of HCN channels, slowing activation and causing a hyperpolarising shift in voltage-dependence of activation. It also reduced Ih-mediated sag in mouse neurons. Org 34167 (0.5 mg/kg) reduced marble burying and increased the time spent mobile in the Porsolt swim and tail suspension tests in both male and female BALB/c mice, suggesting reduced depressive-like behaviour. Although no adverse effects were seen at 0.5 mg/kg, an increase in dose to 1 mg/kg resulted in visible tremors and impaired locomotion and coordination. These data support the premise that HCN channels are valid targets for anti-depressive drugs albeit with a narrow therapeutic index. Drugs with higher HCN subtype selectivity are needed to establish if a wider therapeutic window can be obtained.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2023.1159527

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Effect of Org 34,167 on HCN channels in HEK293 cells. (A) Representative steady-state current traces for vehicle (top panel) and 10 µM Org 34,167 (bottom panel) on HCN1, HCN2 and HCN4 channels, elicited from the activation protocol shown in between the HCN4 traces. Chemical structure of Org 34,167 inset between panels. (B) Org 34,167 dose-response curves (0.03–100 µM) and IC50 values in HEK293 cells expressing HCN1, HCN2 or HCN4 channels. The current (I) data of independent measurements consists of proportional inhibition values of Org 34,167 calculated from tail current measurements at −110 mV, normalised to untreated controls. (C) Org 34,167 dose-response curves of ΔV 0.5 (shifts in the voltage of half-maximal activation) in HEK293 cells expressing human HCN1, HCN2 or HCN4 channels. The ΔV 0.5 values were calculated from normalised current data before and after Org 34,167 administration for each individual cell. (D–F) Voltage-dependence of activation time constants (Tauact) of (D) HCN1, (E) HCN2 or (F) HCN4 channels in the absence or presence of 10 µM Org 34,167, obtained from fitting activation current traces with single-exponential function. N = 2–19 cells per concentration per channel for (A–F). Data represented as mean ± S.E.M, with individual values where relevant. *p < 0.05.
FIGURE 1 Effect of Org 34,167 on HCN channels in HEK293 cells. (A) Representative steady-state current traces for vehicle (top panel) and 10 µM Org 34,167 (bottom panel) on HCN1, HCN2 and HCN4 channels, elicited from the activation protocol shown in between the HCN4 traces. Chemical structure of Org 34,167 inset between panels. (B) Org 34,167 dose-response curves (0.03–100 µM) and IC50 values in HEK293 cells expressing HCN1, HCN2 or HCN4 channels. The current (I) data of independent measurements consists of proportional inhibition values of Org 34,167 calculated from tail current measurements at −110 mV, normalised to untreated controls. (C) Org 34,167 dose-response curves of ΔV 0.5 (shifts in the voltage of half-maximal activation) in HEK293 cells expressing human HCN1, HCN2 or HCN4 channels. The ΔV 0.5 values were calculated from normalised current data before and after Org 34,167 administration for each individual cell. (D–F) Voltage-dependence of activation time constants (Tauact) of (D) HCN1, (E) HCN2 or (F) HCN4 channels in the absence or presence of 10 µM Org 34,167, obtained from fitting activation current traces with single-exponential function. N = 2–19 cells per concentration per channel for (A–F). Data represented as mean ± S.E.M, with individual values where relevant. *p < 0.05.CC BY · PubMed Central
FIGURE 2 Org 34,167 (30 µM) significantly reduces sag in layer V pyramidal neurons. (A) Average of sag traces obtained from cells from female BALB/c mice (n = 4) before (black) and after (blue) Org 34,167 administration from slice electrophysiology recordings. Dotted line (grey) indicates maximal sag. Sag was elicited with (A) 70 pA current injection from (A) 70 mV holding membrane potential (Vm). (B) Comparison of sag before and after Org 34,167 administration (n = 4). ***p < 0.001.
FIGURE 2 Org 34,167 (30 µM) significantly reduces sag in layer V pyramidal neurons. (A) Average of sag traces obtained from cells from female BALB/c mice (n = 4) before (black) and after (blue) Org 34,167 administration from slice electrophysiology recordings. Dotted line (grey) indicates maximal sag. Sag was elicited with (A) 70 pA current injection from (A) 70 mV holding membrane potential (Vm). (B) Comparison of sag before and after Org 34,167 administration (n = 4). ***p < 0.001.CC BY · PubMed Central
FIGURE 3 Behavioural characterisation of Org 34,167 (0.3, 0.5, and 1 mg/kg) in male C57BL/6J and BALB/c mice. (A) Effect of Org 34,167 on time active and total distance travelled in open field test (n = 8–16/group), number of foot faults in ledged beam test (n = 5/group), and time to fall in rotarod test (n = 5/group), in male C57BL/6J mice. (B) Effect of Org 34,167 on male BALB/c mice on time active and total distance travelled in open field test (n = 8–18/group), number of foot faults in ledged beam test (n = 5/group), and time to fall in rotarod test (n = 5/group). Data represented as individual values and mean ± S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.00001, one-way ANOVA with Dunnett’s post-hoc.
FIGURE 3 Behavioural characterisation of Org 34,167 (0.3, 0.5, and 1 mg/kg) in male C57BL/6J and BALB/c mice. (A) Effect of Org 34,167 on time active and total distance travelled in open field test (n = 8–16/group), number of foot faults in ledged beam test (n = 5/group), and time to fall in rotarod test (n = 5/group), in male C57BL/6J mice. (B) Effect of Org 34,167 on male BALB/c mice on time active and total distance travelled in open field test (n = 8–18/group), number of foot faults in ledged beam test (n = 5/group), and time to fall in rotarod test (n = 5/group). Data represented as individual values and mean ± S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.00001, one-way ANOVA with Dunnett’s post-hoc.CC BY · PubMed Central
FIGURE 4 Marble burying, tail suspension and Porsolt swim test data in male C57BL/6J (top) and BALB/c (bottom) mice. Effect of Org 34,167 (0.3 and 0.5 mg/kg) and/or fluoxetine (10 mg/kg; Fluox) as positive control on number of marbles buried by male (A) C57BL/6J and (D) BALB/c mice, and on the immobility time in (B, E) tail suspension and (C, F) Porsolt swim test in male (B, C) C57BL/6J and (E, F) BALB/c mice. Data are represented as individual values and mean ± S.E.M (n ≥ 10/group; *p < 0.05, **p < 0.01, ****p < 0.0001; one-way ANOVA with Dunnett’s post-hoc).
FIGURE 4 Marble burying, tail suspension and Porsolt swim test data in male C57BL/6J (top) and BALB/c (bottom) mice. Effect of Org 34,167 (0.3 and 0.5 mg/kg) and/or fluoxetine (10 mg/kg; Fluox) as positive control on number of marbles buried by male (A) C57BL/6J and (D) BALB/c mice, and on the immobility time in (B, E) tail suspension and (C, F) Porsolt swim test in male (B, C) C57BL/6J and (E, F) BALB/c mice. Data are represented as individual values and mean ± S.E.M (n ≥ 10/group; *p < 0.05, **p < 0.01, ****p < 0.0001; one-way ANOVA with Dunnett’s post-hoc).CC BY · PubMed Central
FIGURE 5 Marble burying, tail suspension and Porsolt swim test data in female mice. Effect of Org 34,167 (0.5 mg/kg) and/or fluoxetine (10 mg/kg; Fluox) as positive control on (A) number of marbles buried by female BALB/c mice, and on the immobility time in (B) tail suspension and (C) Porsolt swim test in female BALB/c mice. Data represented as individual values and mean ± S.E.M (n ≥ 10/group; *p < 0.05, **p < 0.01, ****p < 0.0001; one-way ANOVA with Dunnett’s post-hoc).
FIGURE 5 Marble burying, tail suspension and Porsolt swim test data in female mice. Effect of Org 34,167 (0.5 mg/kg) and/or fluoxetine (10 mg/kg; Fluox) as positive control on (A) number of marbles buried by female BALB/c mice, and on the immobility time in (B) tail suspension and (C) Porsolt swim test in female BALB/c mice. Data represented as individual values and mean ± S.E.M (n ≥ 10/group; *p < 0.05, **p < 0.01, ****p < 0.0001; one-way ANOVA with Dunnett’s post-hoc).CC BY · PubMed Central
FIGURE 6 Impact of Org 34,167 on heart rate. Effect of Org 34,167 (0.5 and 1 mg/kg) on the average heart rate of male (A) and female (B) BALB/c mice over a 35-min monitoring period. Data represented as individual values and mean ± S.E.M (n = 6–8/group; **p ≤ 0.01, ****p ≤ 0.0001, ns, not significant; one-way ANOVA with Dunnett’s post-hoc).
FIGURE 6 Impact of Org 34,167 on heart rate. Effect of Org 34,167 (0.5 and 1 mg/kg) on the average heart rate of male (A) and female (B) BALB/c mice over a 35-min monitoring period. Data represented as individual values and mean ± S.E.M (n = 6–8/group; **p ≤ 0.01, ****p ≤ 0.0001, ns, not significant; one-way ANOVA with Dunnett’s post-hoc).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 4

  1. AdisInsight, 2009, Drug profile: Org 34167
  2. 2001, Australia and New Zealand Council for the Care of animals in research and testing euthanasia of animals used for scientific Purposes
  3. Leysen, 1997, Substituted benzylamines and their use for the treatment of depression
  4. Ward, 2011, Ih Channel inhibitors for the promotion of wakefulness

Cited by

See all 15

Metadata

Authors
Pinares-Garcia, P., Spyrou, J., McKenzie, C. E., Forster, I. C., Soh, M. S., Mohamed Syazwan, E., Atif, M., & Reid, C. A.
Affiliations
The University of Melbourne (AU)
Corresponding author
Reid, Christopher A.
Venue
Frontiers in Pharmacology
Published
2023-05-10
Volume
14
Pages
1159527-1159527
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4378515463
Cited by
15
References
54
Citations by year
2026: 3 · 2025: 5 · 2024: 5 · 2023: 2
FWCI
2.33
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • National Health and Medical Research Council (10915693)
  • Australian Government (Research Training Program Scholarship)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
HCN channels, benzisoxazoles, antidepressant-like effects, depression, voltage dependence of activation, depression-like behavior, tremor, therapeutic window

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antidepressant-like activity of a brain penetrant HCN channel inhibitor in mice. https://app.cochat.ai/papers/10.3389/fphar.2023.1159527
The paper
Pinares-Garcia, P., Spyrou, J., McKenzie, C. E., Forster, I. C., Soh, M. S., Mohamed Syazwan, E., Atif, M., & Reid, C. A. (2023). Antidepressant-like activity of a brain penetrant HCN channel inhibitor in mice. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1159527

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.